Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“A simple comparison of Teclistamab studies in relapsed multiple myeloma – single agent versus combination therapy, and early versus late relapse settings.”
Other articles featuring Dr. Abdallah on OncoDaily.